|
1
|
Bush NA, Chang SM and Berger MS: Current
and future strategies for treatment of glioma. Neurosurg Rev.
40:1–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hempel JM, Schittenhelm J, Brendle C,
Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda VS, Ernemann
U and Klose U: Effect of perfusion on diffusion kurtosis imaging
estimates for in vivo assessment of integrated 2016 WHO glioma
grades: A cross-sectional observational study. Clin Neuroradiol.
1-11:2017.https://doi.org/10.1007/s00062-017-0606-8
|
|
3
|
Feng X, Yu Y, He S, Cheng J, Gong Y, Zhang
Z, Yang X, Xu B, Liu X, Li CY, et al: Dying glioma cells establish
a proangiogenic microenvironment through a caspase 3 dependent
mechanism. Cancer Lett. 385:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Madsen SJ, Christie C, Hong SJ, Trinidad
A, Peng Q, Uzal FA and Hirschberg H: Nanoparticle-loaded
macrophage-mediated photothermal therapy: Potential for glioma
treatment. Lasers Med Sci. 30:1357–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Munoz JL, Rodriguez-Cruz V, Ramkissoon SH,
Ligon KL, Greco SJ and Rameshwar P: Temozolomide resistance in
glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic
hedgehog level. Oncotarget. 6:1190–1201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su Y, He Q, Deng L, Wang J, Liu Q, Wang D,
Huang Q and Li G: MiR-200a impairs glioma cell growth, migration,
and invasion by targeting SIM2-s. Neuroreport. 25:12–17.
2014.PubMed/NCBI
|
|
7
|
Ganju A, Khan S, Hafeez BB, Behrman SW,
Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for
cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jonas S and Izaurralde E: Towards a
molecular understanding of microRNA-mediated gene silencing. Nat
Rev Genet. 16:421–433. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ning X, Shi Z, Liu X, Zhang A, Han L,
Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation
silences the microRNA-200b/a/429 gene and promotes tumor
progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia H, Ng SS, Jiang S, Cheung WKC, Sze J,
Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of
ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma
cell growth, migration and invasion. Biochem Biophys Res Commun.
391:535–541. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng J, Wang J, Chen M, Chen G, Wu Z, Ying
L, Zhuo Q, Zhang J and Wang W: miR-200a suppresses cell growth and
migration by targeting MACC1 and predicts prognosis in
hepatocellular carcinoma. Oncol Rep. 33:713–720. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao J, Zhou E, Wang Y, Xu F, Zhang D and
Zhong D: microRNA-200a inhibits cell proliferation by targeting
mitochondrial transcription factor A in breast cancer. DNA Cell
Biol. 33:291–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berthois Y, Delfino C, Metellus P, Fina F,
Nanni-Metellus I, Al Aswy H, Pirisi V, Ouafik L and Boudouresque F:
Differential expression of miR200a-3p and miR21 in grade II–III and
grade IV gliomas: Evidence that miR200a-3p is regulated by
O6-methylguanine methyltransferase and promotes
temozolomide responsiveness. Cancer Biol Ther. 15:938–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su Y, He Q, Deng L, Wang J, Liu Q, Wang D,
Huang Q and Li G: MiR-200a impairs glioma cell growth, migration,
and invasion by targeting SIM2-s. Neuroreport. 25(12)2014.7.
PubMed/NCBI
|
|
17
|
Ma CC, Xiong Z, Zhu GN, Wang C, Zong G,
Wang HL, Bian EB and Zhao B: Long non-coding RNA ATB promotes
glioma malignancy by negatively regulating miR-200a. J Exp Clin
Cancer Res. 35:902016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: MiR-130a and miR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 cells. PLoS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elhag R, Mazzio EA and Soliman KF: The
effect of silibinin in enhancing toxicity of temozolomide and
etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Anticancer Res. 35:1263–1269. 2015.PubMed/NCBI
|
|
20
|
Prieto-Vila M, Takahashi RU, Usuba W,
Kohama I and Ochiya T: Drug resistance driven by cancer stem cells
and their niche. Int J Mol Sci. 18:E25742017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X,
Zhu Y and Yang P: The effects and molecular mechanisms of MiR-106a
in multidrug resistance reversal in human glioma U87/DDP and U251/G
cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi L, Chen J, Yang J, Pan T, Zhang S and
Wang Z: MiR-21 protected human glioblastoma U87MG cells from
chemotherapeutic drug temozolomide induced apoptosis by decreasing
Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352:255–264.
2010. View Article : Google Scholar : PubMed/NCBI
|
